P-207: A multi-center, phase 1b study to assess the safety, Pharmacokinetics and efficacy of subcutaneous Isatuximab plus Pomalidomide and Dexamethasone, in patients with Relapsed/Refractory Multiple Myeloma [vol 21, Pg S152, 2021)

Por: Moreau, P, Parmar, G, Prince, M, Ocio, EM, Karanes, C, Madan, S, Oriol, A, Bories, P, Delforge, M, Gabrail, N, Semiond, D, Jia, N, Macc, S, Suzan, F, van de Velde, H and Quach, H

---

Publicada: 1 jun 2022 Ahead of Print: 1 may 2022

---

---

Filiaciones:
Moreau, P:
 Univ Hosp Nantes, Nantes, France

Parmar, G:
 Illawarra Canc Care Ctr, Wollongong, NSW, Australia

Prince, M:
 Epworth Healthcare, Melbourne, Vic, Australia

 Univ Melbourne, Melbourne, Vic, Australia

Ocio, EM:
 Univ Cantabria, Santander, Spain

Karanes, C:
 City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA

Madan, S:
 Banner MD Anderson Canc Ctr, Gilbert, AZ USA

:
 Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Barcelona, Spain

 Hosp Badalona Germans Trias & Pujol, Inst Josep Carreras, Barcelona, Spain

Bories, P:
 Reseau Reg Cancerol Oncoccitanie, Toulouse, France

Delforge, M:
 Univ Hosp Leuven, Leuven, Belgium

Gabrail, N:
 Gabrail Canc Ctr, Canton, OH USA

Semiond, D:
 Sanofi, Cambridge, MA USA

Jia, N:
 Sanofi, Cambridge, MA USA

Macc, S:
 Sanofi, Vitry Sur Seine, France

Suzan, F:
 Sanofi, Vitry Sur Seine, France

van de Velde, H:
 Sanofi, Cambridge, MA USA

Quach, H:
 Univ Melbourne, St Vincents Hosp, Melbourne, Vic, Australia